Temporal and spatial variability of immunosuppressive therapies in transplant patients: An observational study in Italy.

drug utilization immunosuppressive therapy real-world evidence solid organ transplant space–time variability

Journal

Frontiers in transplantation
ISSN: 2813-2440
Titre abrégé: Front Transplant
Pays: Switzerland
ID NLM: 9918573988006676

Informations de publication

Date de publication:
2022
Historique:
received: 03 10 2022
accepted: 23 11 2022
medline: 16 1 2023
pubmed: 16 1 2023
entrez: 12 7 2024
Statut: epublish

Résumé

In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors ( An Italian multicentre observational cohort study was conducted using health information systems. Patients with incident transplant during 2009-2019 and resident in four regions (Veneto, Lombardy, Lazio, and Sardinia) were enrolled. The post-transplant immunosuppressive regimen was evaluated by organ, region, and year. The most dispensed regimen was triple-drug therapy for the kidneys [tacrolimus (TAC) + antiM + corticosteroids = 41.5%] and heart [cyclosporin  + antiM + corticosteroids = 36.6%] and double-drug therapy for liver recipients (TAC + corticosteroids = 35.4%). Several differences between regions and years emerged with regard to agents and the number of drugs used. A high heterogeneity in immunosuppressive therapy post-transplant was found. Further studies are needed in order to investigate the reasons for this variability and to evaluate the risk-benefit profile of treatment schemes adopted in clinical practice.

Sections du résumé

Background UNASSIGNED
In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors (
Methods UNASSIGNED
An Italian multicentre observational cohort study was conducted using health information systems. Patients with incident transplant during 2009-2019 and resident in four regions (Veneto, Lombardy, Lazio, and Sardinia) were enrolled. The post-transplant immunosuppressive regimen was evaluated by organ, region, and year.
Results UNASSIGNED
The most dispensed regimen was triple-drug therapy for the kidneys [tacrolimus (TAC) + antiM + corticosteroids = 41.5%] and heart [cyclosporin  + antiM + corticosteroids = 36.6%] and double-drug therapy for liver recipients (TAC + corticosteroids = 35.4%). Several differences between regions and years emerged with regard to agents and the number of drugs used.
Conclusion UNASSIGNED
A high heterogeneity in immunosuppressive therapy post-transplant was found. Further studies are needed in order to investigate the reasons for this variability and to evaluate the risk-benefit profile of treatment schemes adopted in clinical practice.

Identifiants

pubmed: 38994384
doi: 10.3389/frtra.2022.1060621
pmc: PMC11235261
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1060621

Informations de copyright

© 2023 Marino, Rosa, Finocchietti, Bellini, Poggi, Massari, Alegiani, Masiero, Ricci, Bedeschi, Puoti, Cardillo, Pierobon, Nordio, Ferroni, Zanforlini, Piccolo, Leoni, Ledda, Carta, Garau, Lucenteforte, Davoli, Addis and Belleudi.

Déclaration de conflit d'intérêts

MZ was employed by ARIA, S.p.a. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Maria Lucia Marino (ML)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Alessandro C Rosa (AC)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Marco Finocchietti (M)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Arianna Bellini (A)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Francesca R Poggi (FR)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Marco Massari (M)

National Center for Drug Research and Evaluation, Istituto Superiore Di Sanità, Rome, Italy.

Stefania Spila Alegiani (S)

National Center for Drug Research and Evaluation, Istituto Superiore Di Sanità, Rome, Italy.

Lucia Masiero (L)

Italian National Transplant Center, Istituto Superiore di Sanità, Rome, Italy.

Andrea Ricci (A)

Italian National Transplant Center, Istituto Superiore di Sanità, Rome, Italy.

Gaia Bedeschi (G)

Italian National Transplant Center, Istituto Superiore di Sanità, Rome, Italy.

Francesca Puoti (F)

Italian National Transplant Center, Istituto Superiore di Sanità, Rome, Italy.

Massimo Cardillo (M)

Italian National Transplant Center, Istituto Superiore di Sanità, Rome, Italy.

Silvia Pierobon (S)

Azienda Zero of the Veneto Region, Padua, Italy.

Maurizio Nordio (M)

Azienda Zero of the Veneto Region, Padua, Italy.

Eliana Ferroni (E)

Azienda Zero of the Veneto Region, Padua, Italy.

Martina Zanforlini (M)

Azienda Regionale per l'Innovazione e gli Acquisti, ARIA, S.p.A., Milan, Italy.

Giuseppe Piccolo (G)

Regional Transplant Coordination, Milan, Italy.

Olivia Leoni (O)

Directorate General for Health, Milan, Italy.

Stefano Ledda (S)

General Directorate for Health, Cagliari, Italy.

Paolo Carta (P)

General Directorate for Health, Cagliari, Italy.

Donatella Garau (D)

General Directorate for Health, Cagliari, Italy.

Ersilia Lucenteforte (E)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Marina Davoli (M)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Antonio Addis (A)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Valeria Belleudi (V)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Classifications MeSH